ADPKD Guide
Readable, evidence-first ADPKD treatment, symptoms, diet, trials, and research updates for patients, families, and clinicians.
Last sweep: Jun 1, 2026
What’s New Methodology References Support GitHub
Ask ADPKD Patient Guide Treatment Slow Progression Trials Cure
More
What’s New Newly Diagnosed Tolvaptan Lifestyle Diet Symptoms Clinicians Methodology References Support
ADPKD Cure Research Research Status Overview

Is there a cure for ADPKD?

Short answer: no proven cure in humans yet. Longer answer: serious cure-focused research is underway, but it is in early clinical and preclinical phases. Here is what is real, what is hype, and what to watch.

Last reviewed: July 23, 2026

What we have now — and what we do not

What exists Proven

  • Tolvaptan — slows progression in appropriate adults. Not a cure. Requires monitoring.
  • Blood pressure control — strong evidence for slowing progression indirectly. Standard care.
  • Risk stratification — tells you how fast you are progressing, enabling smarter decisions.

What does NOT exist yet Not proven

  • A drug that stops cyst growth entirely
  • A gene therapy approved for human use in ADPKD
  • Any supplement, diet, or alternative treatment that has passed a controlled ADPKD trial for curative effect

Why people claim a cure exists — and why they are wrong

A few patterns produce false "cure" narratives online:

  • Preclinical results framed as patient-ready — mice or cell culture results that look dramatic, reported as "scientists find cure." Every failed drug started as a promising animal result.
  • Trial registration ≠ drug works — a company registering a Phase 1 trial means they are testing safety in 10–30 people. It does not mean the drug works.
  • Supplement marketing — no supplement has passed a controlled ADPKD trial. Testimonials and laboratory studies are not clinical evidence.
  • Conflating "slows progression" with "cures" — tolvaptan is real and meaningful. It is not a cure.

What cure-focused research is actually worth watching

Gene editing/therapy correction of causal variants (PKD1/PKD2)

  • **Early clinical signal:** VX-407 Phase 2a (AGLOW) actively recruiting for PKD1-subset variants; started Nov 2025, primary completion ~July 2027. FDA-regulated gene-therapy approach.
  • **Precision-enrollment infrastructure improved:** newly tracked Vertex observational study **NCT06747572** is profiling **PKD1/2 variant groups** and baseline phenotype across roughly **401 ADPKD participants**, with 1-year follow-up in a subset of PKD1 variants. That strengthens trial-matching and genotype-stratification readiness, not efficacy.
  • **Preclinical:** CRISPR-based PKD1/PKD2 cis-inhibition reversal studies (Nature Communications 2022); mechanistic validation that restoring PKD1/PKD2 expression suppresses cystogenesis in models.
  • **Feasibility bottlenecks:** Variant-specific targeting (VX-407 subset), delivery to kidney, off-target immune response, durability of correction, organ-level functional recovery post-reversal.

RNA-targeted correction/silencing strategies

  • **Status:** Preclinical. microRNA-mediated PKD1/PKD2 suppression as target (mechanistic pathway identified; no clinical trials yet).

Cell/organ regenerative replacement concepts

  • **Status:** Exploratory preclinical; no active clinical pipelines identified.

Multi-pathway disease interception (beyond single-target)

  • **Status:** Emerging. Patient-derived adult renal organoids now support human-model screening of cyst biology across genotypes and nominate **Rho/planar-cell-polarity pathway inhibition** as a candidate cyst-reducing strategy (PMID41946363), but this remains preclinical.
  • **Current target clusters:** microvascular/endothelial dysfunction, metabolic reprogramming, immune dysregulation, apelin signaling, ALDH1A1/disulfiram, endocannabinoid/CB1R signaling, and now Rho/PCP signaling.
  • **New preclinical breadth:** apelin agonism reduced cyst growth in PKD mice (PMID41958979); ALDH1A1 inhibition with disulfiram delayed cyst growth and low-dose disulfiram plus PD-L1 blockade looked synergistic in mice (PMID41864666); ECS/CB1R dysregulation tracked with severity in human and murine ADPKD (PMID41840489); and miniaturized CRISPRa vectors improved Pkd1 transactivation delivery in renal epithelial cells (PMID42068455).
  • **Reality check:** Better human modeling is valuable, but none of these pathways has human efficacy proof or a credible cure claim yet.
  • **Gene therapy (PKD1):** ✓ Early clinical (Phase 2a active)
  • **Gene editing (CRISPR):** ○ Preclinical only
  • **RNA/microRNA silencing:** ○ Preclinical only
  • **Regenerative/cellular therapy:** ○ No active programs identified
  • **Metabolic reprogramming targeting:** ○ Preclinical (Ogt inhibition, lipid metabolic drivers in models)
  • **Rho/PCP pathway targeting:** ○ Preclinical (patient-derived organoid screening signal)
  • **Apelin / ALDH1A1 / ECS / CRISPRa delivery:** ○ Preclinical only (mouse, tissue, or in vitro)

Gene therapy — the most advanced cure-focused lane

One Phase 2a trial is running (VX-407 / AGLOW). It targets a specific PKD1 mutation. Results are not yet published. This is real — but early.

What it aims to do: deliver a functional copy of the PKD1 gene to kidney cells, or correct the disease-causing mutation directly using base editing or CRISPR. If it works, it could theoretically halt cyst formation at the genetic root cause.

What stage it is at: the most advanced programme (VX-407 in the AGLOW Phase 2a trial) is testing safety and early efficacy in patients with a specific PKD1 loss-of-function variant. No efficacy data is published as of mid-2026.

Why the timeline is long: gene therapy must prove safety first, then efficacy in small trials, then large trials, then regulatory review. Even with an optimistic path, widespread availability is likely a decade or more away.

Realistic framing: this is genuine scientific progress. It is not a near-term treatment option for most patients. Keep watching trial registries and peer-reviewed publications — not press releases.

RNA-targeted approaches

Antisense oligonucleotides (ASOs) and RNA interference (RNAi) aim to reduce production of harmful or excess protein encoded by the mutant PKD1 or PKD2 gene, without changing the DNA itself.

Status: entirely preclinical as of 2026. Animal models show promise. No human trials have started.

RNA approaches are generally considered safer to deliver than gene editing (no permanent DNA change), but the timeline to human trials is still uncertain.

Regenerative / cellular approaches

Replacing diseased kidney tissue with healthy cells grown from induced pluripotent stem cells (iPSCs) or organoids. Extremely early-stage — there is no current pipeline in human trials for this approach in ADPKD.

Organoids are useful research tools for testing drugs, not therapies in themselves at this stage.

How to follow cure research without being misled

  • ClinicalTrials.gov — the primary source for trial status. Search "polycystic kidney" and look for Phase 2+ trials with recruitment status.
  • PubMed — peer-reviewed results. Preprints and press releases are not the same.
  • ADPKD Guide — this site tracks and tiers cure research in the Findings section and the AI chat can answer specific questions.
  • Watch for: "Phase 2 efficacy results" or "published trial data" — not "company announces promising new approach."

What to ignore

Anything presented as a current cure for ADPKD is false.
  • Social media posts claiming herbs, fasting, or supplements reversed ADPKD
  • Companies selling "ADPKD cure" products
  • Headlines reading "scientists cure PKD in mice" — animal cures have not translated to humans
  • Trial phase 1 announcements framed as near-available treatments
  • Patient testimonials presented as clinical evidence